Michael Carter

Directeur/Membre du Conseil chez ONCTERNAL THERAPEUTICS, INC.

Profil

Michael G.
Carter is an Independent Director at Oncternal Therapeutics, Inc. since 2019 and a Senior Advisor at Healthcare Royalty Management LLC since 2009.
Former roles include Non-Executive Chairman at Metris Therapeutics Ltd. from 1999 to 2008, Director at CancerVax Corp.
from 2001 to 2006, Independent Director at Santarus, Inc. from 2011 to 2013, Non-Executive Director at Fulcrum Pharma Plc from 2005 to 2010, Non-Executive Director at Micromet AG from 2001 to 2005, Non-Executive Director at Amgen Rockville, Inc. from 2006 to 2012, Non-Executive Director at Oncoethix GmbH from 2013 to 2014, Director-Pharmaceutical Division at Roche Products Ltd. from 1976 to 1984, Director-International Medical & Marketing at Zeneca Pharmaceuticals from 1985 to 1995, Venture Partner at SV Health Investors LLP from 1998 to 2016, and Member-Pharmaceutical Board at AstraZeneca, Inc. from 1984 to 1998.
Other former positions include Director roles at Artios Pharma Ltd., Warner Chilcott Plc, GTx, Inc., Oxagen Ltd., Fulcrum Ltd., Atopix Therapeutics Ltd., Oncternal Oncology, Inc., and Independent Director at various firms.
Education includes a doctorate from The University of Sheffield and an undergraduate degree from UCL School of Pharmacy.

Postes actifs de Michael Carter

Sociétés	Poste	Début
ONCTERNAL THERAPEUTICS, INC.	Directeur/Membre du Conseil	07/06/2019
Healthcare Royalty Management LLC	Consultant / Advisor	01/01/2009

Anciens postes connus de Michael Carter

Sociétés	Poste	Fin
Oxagen Ltd.	Directeur/Membre du Conseil	22/08/2017
SV Health Investors LLP	Private Equity Investor	01/01/2016
OncoEthix SA	Directeur/Membre du Conseil	01/12/2014
Santarus, Inc.	Directeur/Membre du Conseil	01/01/2013
Amgen Rockville, Inc.	Directeur/Membre du Conseil	01/03/2012